Nifekalant hydrochloride for patients with cardiac arrest caused by shockable rhythm

Circulation Journal

Volumn 74, Issue 11, 2010, Pages 2285-2287

  Nagao, Ken ^a  

^a SURUGADAI NIHON UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; AMIODARONE; LIDOCAINE; MAGNESIUM SULFATE; NIFEKALANT; PROCAINAMIDE; VASOPRESSIN;

CARDIOPULMONARY BYPASS; CLINICAL EFFECTIVENESS; DEFIBRILLATION; DRUG CLASSIFICATION; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG RESPONSE; EDITORIAL; HEART ARREST; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; INCIDENCE; INDUCED HYPOTHERMIA; OUTCOMES RESEARCH; QT PROLONGATION; RESUSCITATION; SURVIVAL RATE;

ANTI-ARRHYTHMIA AGENTS; DEFIBRILLATORS; ELECTRIC COUNTERSHOCK; HUMANS; OUT-OF-HOSPITAL CARDIAC ARREST; PATIENT ADMISSION; PYRIMIDINONES; SURVIVAL RATE; TACHYCARDIA, VENTRICULAR; TIME FACTORS; TORSADES DE POINTES; TREATMENT FAILURE; VENTRICULAR FIBRILLATION;

EID: 78449256906     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-0936     Document Type: Editorial

References (22)

1. 2005 International Liaison Committee on Resuscitation. 2005 International Consensus Conference on cardiopulmonary resuscitation and emergency cardiovascular care science with treatment recommendations. Circulation 2005; 112: III-1-III-136.
2. American Heart Association. 2005 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation 2005; 112: IV-1-IV-205.
3. Kitamura T, Iwami T, Kawamura T, Nagao K, Tanaka H, Hiraide A. Nationwide public-access defibrillation in Japan. N Engl J Med 2010; 362: 994-1004.
4. SOS-KANTO committee. Incidence of ventricular fibrillation in patients with out-of-hospital cardiac arrest. Circ J 2005; 69: 1157-1162.
5. SOS-KANTO study group. Cardiopulmonary resuscitation by bystanders with chest compression only (SOS-KANTO): An observational study. Lancet 2007; 367: 920-926.
6. Nakaya H, Tohse N, Takeda Y, Kanno M. Effects of MS-551, a new class III antiarrhythmic drug, on action potential and membrane currents in rabbit ventricular myocytes. Br J Pharmacol 1993; 109: 157-163.
7. Cheng J, Kamiya K, Kodama I, Toyama J. Differential effects of MS-551 and E-4031 on action potentials and the delayed rectifier K+ current in rabbit ventricle myocytes. Cardiovasc Res 1996; 31: 963-974.
8. Murakawa Y, Yamashita T, Kanese Y, Omata M. Can a class III antiarrhythmic drug improve electrical defibrillation efficacy during ventricular fibrillation? J Am Coll Cardiol 1997; 29: 688-692.
9. Sahara M, Sagara K, Yamashita T, Iinuma H, Fu LT, Watanabe H. Nifekalant hydrochloride, a novel a class III anti-arrhythmic agent, suppressed postoperative recurrent ventricular tachycardia in a patients undergoing coronary artery bypass grafting and the Dor approach. Circ J 2003; 67: 712-714.
10. Myoishi M, Yasuda S, Miyazaki S, Uneo K, Morii I, Otsuka Y, et al. Intravenous administration of nifekalant hydrochloride for the prevention of ischemia-induced ventricular tachyarrhythmia in patients with renal failure undergoing hemodialysis. Circ J 2003; 67: 898-900.
11. Amino M, Yamazaki M, Nakagawa H, Honjo H, Okuno Y, Yoshioka K, et al. Combined effects of nifekalant and lidocaine on the spiraltype re-entry in a perfused 2-dimensional layer of rabbit ventricular myocardium. Circ J 2005; 69: 576-584.
12. Hirose M, Miura M, Wakayama Y, Endo H, Sugai Y, Stuyvers B, et al. Effect of nifekalant, a class III anti-arrhythmic agent, on Ca2+ waves in rat intact trabeculae. Circ J 2005; 69: 739-745.
13. Katoh T, Mitamura H, Matsuda N, Takano T, Ogawa S, Kasanuki H. Emergency treatment with nifekalant, a novel class III anti-arrhythmic agent, for life-threatening refractory ventricular tachyarrhythmia: Post-marketing special investigation. Circ J 2005; 69: 1237-1243.
14. Washizuka T, Chinushi M, Watanabe H, Hosaka Y, Komura S, Sugiura H, et al. Nifekalant hydrochloride suppresses severe electrical storm in patients with malignant ventricular tachyarrhythmia. Circ J 2005; 69: 1508-1513.
15. Yoshioka K, Amino M, Morita S, Nakagawa Y, Usui K, Sugimoto A, et al. Can nifekalant hydrochloride be used as a first-line drug for cardiopulmonary arrest (CPA)?: Comparative study of out-ofhospital CPA with acidosis and in-hospital CPA without acidosis. Circ J 2006; 70: 21-27.
16. Tahara Y, Kimura K, Kosuge M, Ebina T, Sumita S, Hibi K, et al. Comparison of nifekalant and lidocaine for the treatment of shockrefractory ventricular fibrillation. Circ J 2006; 70: 442-446.
17. Watanabe H, Chinushi M, Washizuka T, Sugiura H, Hirono T, Aizawa Y, et al. Comparison of efficacy of sotalol and nifekalant for ventricular tachyarrhythmias. Circ J 2006; 70: 583-587.
18. Yoshioka K, Amino M, Usui K, Sugimoto A, Matsuzaki A, Kohzuma K, et al. Nifekalant hydrochloride administration during cardiopulmonary resuscitation improves the transmural dispersion of myocardial repolarization: Experimental study in a canine model of cardiopulmonary arrest. Circ J 2006; 70: 1200-1207.
19. Okishige K, Uehara H, Miyagi N, Nakamura K, Azegami K, Wakimoto H, et al. Clinical study of the acute effects of intravenous nifekalant on the defibrillation threshold in patients with persistent and paroxysmal atrial fibrillation. Circ J 2008; 72: 76-80.
20. Yusu S, Ikeda T, Mera H, Miyakoshi M, Miwa Y, Abe A, et al. Effects of nifekalant as a lifesaving drug for severe ventricular tachyarrhythmias complicating acute coronary syndrome. Circ J 2009; 73: 2021-2028.
21. Miwa Y, Ikeda T, Mera H, Miyakoshi M, Hoshida K, Yanagisawa R, et al. Effects of landiolol, an ultra-short-acting ß1-selective blocker, on electrical storm refractory to class III antiarrhythmic drugs. Circ J 2010; 74: 856-863.
22. Yasuda S, Sawano H, Hazui H, Ukai I, Yokoyama H, Ohashi J, et al on behalf of the J-PULSE Investigators. Report from J-PULSE muliticenter registry of patients with shock-resistant out-of-hospital cardiac arrest treated with nifekalant hydrochloride. Circ J 2010; 74: 2308-2313.